FQHCs excel in kidney disease testing for at-risk populations

Federally Qualified Health Centers (FQHCs) are leading the way in guideline-adherent kidney disease testing, even while serving socially at-risk populations. The article highlights the critical role FQHCs play in delivering high-quality care and reducing gaps in chronic disease management. Dive into the data and read the study here: https://lnkd.in/ghp8jiQh #FQHC #kidneydisease #improvinghealthoutcomes # #clinicalguidelines

Federally Qualified Health Centers (FQHCs) are leading the way in guideline-adherent kidney disease testing, even while serving socially at-risk populations. The article highlights the critical role FQHCs play in delivering high-quality care and reducing gaps in chronic disease management. Dive into the data and read the study here: https://lnkd.in/gS2-SDzq #FQHC #kidneydisease #improvinghealthoutcomes # #clinicalguidelines

Federally Qualified Health Centers (FQHCs) are leading the way in guideline-adherent kidney disease testing, even while serving socially at-risk populations. The article highlights the critical role FQHCs play in delivering high-quality care and reducing gaps in chronic disease management. Dive into the data and read the study here: #FQHC #kidneydisease #improvinghealthoutcomes # #clinicalguidelines

Predicted the rise of XFG (STRATUS) in July 2025 before WHO VUM designation. Built synthetic models with F486P, L452W, Q493E now defining its immune escape profile. Invivyd's VYD2311? Potent against yesterday’s variants. But against tomorrow’s XFG-driven world? Unlikely to last >10 months. mAbs should be trained on future evolution not past. #SARSCoV2 #XFG #MonoclonalAntibodies #ComputationalVirology #VariantMonitoring Invivyd | World Health Organization | Centers for Disease Control and Prevention

Research into long COVID has surged beyond the levels previously seen for other infection-associated chronic illnesses (IACIs) 📈 This has a major potential benefit for these pre-existing IACIs: the scale and clear infectious trigger of long COVID is helping to draw attention and legitimacy towards a set of extremely neglected diseases. However, there has been a clear tendency of long COVID researchers to believe they are starting entirely from scratch, which they need not. Instead we must also push these researchers and groups to learn from and integrate their work into the existing research around ME/CFS, POTS, MCAS, dysautonomia etc - many of which can be COVID-triggered, falling under the long COVID umbrella. That way, progress can be accelerated for everyone - including long COVID patients 🚀 #MECFS #LongCOVID #POTS #Dysautonomia

The overall impact of public health measures during COVID-19 on the prenatal diagnosis of congenital heart disease (CHD) has received limited attention. Eckersley et al. investigate this in their #openaccess study, finding that despite reduction in clinical services during the pandemic, the rate of prenatal diagnosis of critical CHD continued to increase. Read the #UOGJournal now: https://bit.ly/42mG7t7 #EveryLittleHeartMatters 💕

📚New #JAPSCJournal Article: "Main Challenges and Solutions Facing ACHD in Asia-Pacific" 📚 Adult congenital heart disease is a rising challenge across the Asia-Pacific region 📊. From delayed diagnoses to fragmented care, this article explores key barriers and practical solutions to improve outcomes. A coordinated, regional approach is critical. #RadcliffeJournals 📖📑 👉 http://ow.ly/pxyn106o2Sz

PFCD recently had a chance to catch up with National Organization for Rare Disorders' Pamela Gavin on the impacts of adopting "Most Favored Nation" and foreign reference pricing on people's access to lifesaving therapies for rare diseases. Listen here: https://lnkd.in/etYCw3pg #Fight4Health

🫀 29 September is globally observed as #WorldHeartDay to raise awareness of cardiovascular diseases (CVD) and promote heart health. In the EU, Joint Action JACARDI has the mission of supporting EU countries in reducing the burden of CVD and diabetes by coordinating evidence-based interventions and knowledge-sharing. Funded under #EU4Health, JACARDI is implementing 143 pilot projects, collaborating to ensure that effective practices across Europe are maintained, adapted and expanded upon. The initiative intervenes across the stages of the entire patient journey: 🩵 Prevention through health literacy and awareness-raising 🔍 Screening of high-risk populations and individuals 🌐 Integrated care pathways 🙌 Empowerment of diagnosed individuals through self-management of health and promotion of healthy behaviours Learn more on JACARDI's website: https://jacardi.eu/

Venous thromboembolism (VTE), which includes pulmonary embolism (PE), is a serious condition. With increased awareness, early diagnosis, and timely treatment, many cases can be prevented (1). This #WorldThrombosisDay, BD stands with the global community to raise awareness about thrombosis and its impact on health. Learn more about how venous diseases contribute to thrombosis and how they can be treated: https://bit.ly/476t40i #WorldThrombosisDay #PreventThrombosis (1) Kang M, Schreiber R, Baris VK, et al. Delayed Venous Thromboembolism Diagnosis and Mortality Risk. JAMA Netw Open. 2025;8(9):e2533928. doi:10.1001/jamanetworkopen.2025.33928